VOLPINI, Rosaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.012
EU - Europa 5.557
AS - Asia 2.195
Continente sconosciuto - Info sul continente non disponibili 49
SA - Sud America 23
AF - Africa 6
OC - Oceania 6
Totale 21.848
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.553
CN - Cina 1.922
PL - Polonia 1.482
IT - Italia 1.075
DE - Germania 775
UA - Ucraina 528
SE - Svezia 489
CA - Canada 454
GB - Regno Unito 429
FR - Francia 260
FI - Finlandia 235
IE - Irlanda 126
SG - Singapore 106
EU - Europa 49
BE - Belgio 38
VN - Vietnam 38
CZ - Repubblica Ceca 32
IN - India 25
TR - Turchia 24
IR - Iran 23
KR - Corea 22
NL - Olanda 17
RO - Romania 17
RU - Federazione Russa 16
HK - Hong Kong 13
AT - Austria 8
BR - Brasile 8
ES - Italia 8
CL - Cile 6
DK - Danimarca 6
AU - Australia 5
EC - Ecuador 4
JP - Giappone 4
LB - Libano 4
GR - Grecia 3
RS - Serbia 3
TH - Thailandia 3
CH - Svizzera 2
CO - Colombia 2
DZ - Algeria 2
GT - Guatemala 2
JO - Giordania 2
MX - Messico 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TW - Taiwan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BD - Bangladesh 1
BG - Bulgaria 1
BT - Bhutan 1
CM - Camerun 1
CR - Costa Rica 1
HR - Croazia 1
KE - Kenya 1
KZ - Kazakistan 1
LV - Lettonia 1
MD - Moldavia 1
MT - Malta 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
QA - Qatar 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
Totale 21.848
Salva come PNG Salva come JPEG
Città #
Fairfield 1.762
Woodbridge 1.493
Jacksonville 1.322
Warsaw 1.294
Chandler 1.053
Houston 1.045
Ashburn 888
Seattle 767
Wilmington 751
Ann Arbor 647
Cambridge 605
Nanjing 459
Toronto 319
San Mateo 199
Camerino 196
Boardman 190
Dearborn 188
Kraków 185
Lawrence 180
Princeton 180
Beijing 165
Düsseldorf 164
Columbus 152
Ogden 146
Lachine 128
Dublin 125
Nanchang 123
London 101
Helsinki 89
Shenyang 87
San Diego 84
Shanghai 83
New York 82
Tianjin 80
Kunming 74
Milan 74
Guangzhou 73
Hebei 62
Jiaxing 55
Singapore 54
Changsha 39
Chicago 39
Redwood City 39
Brussels 38
Ningbo 38
Wuhan 38
Jinan 37
Centro 36
Los Angeles 36
Dong Ket 35
Hangzhou 31
Venezia 31
Zhengzhou 30
Verona 29
Philadelphia 28
Hefei 27
Brno 25
Falls Church 25
Norwalk 25
Orange 24
Jinhua 22
Kocaeli 22
Nürnberg 22
Detroit 21
Bremen 20
Taizhou 19
Lanzhou 18
Leawood 17
Perugia 17
Washington 17
Auburn Hills 16
San Francisco 15
Tappahannock 15
Venice 15
Ardabil 14
Changchun 14
Yiwu 14
Munich 13
Frankfurt am Main 12
Scafati 12
Council Bluffs 11
Andover 10
Buffalo 10
Hounslow 10
Acton 9
Ancona 9
Bologna 9
Indiana 9
Kilburn 9
Phoenix 9
Shenzhen 9
Meppel 8
New Bedfont 8
Old Bridge 8
Seoul 8
Simi Valley 8
Granada 7
Hanover 7
Horia 7
Monmouth Junction 7
Totale 16.881
Salva come PNG Salva come JPEG
Nome #
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 324
Overview on Radiolabel-Free in Vitro Assays for GPCRs 310
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 271
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 269
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 259
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 258
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 248
Pharmacological characterization of the GPR17 receptor dual profile 248
The G Protein-Coupled Receptor GPR17: Overview and Update 245
Medicinal chemistry and pharmacology of A2B adenosine receptors 241
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease 233
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 215
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 206
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 205
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 204
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 197
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 191
GPR17 receptor modulators and their therapeutic implications: review of recent patents 184
Human cytidine deaminase: understanding the catalytic mechanism 178
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 177
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 174
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 173
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 167
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 165
Purine and deazapurine nucleosides: synthetic approaches, molecular modeling and biological activity 163
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 161
Human placenta cytidine deaminase: a zinc metalloprotein 160
2-Aralkynyl and 2-Heteroalkynyl derivatives of Adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists 160
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 160
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 156
3'-Deoxyribofuranose derivatives of 1-deaza and 3-deaza adenosine and their activity as adenosine deaminase inhibitors 155
New sensible method to quantize the intestinal absorption of receptor ligands 155
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 154
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 153
Determination of ink photoinitiators in packaged beverages by gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry 153
Isoenzymatic forms of human cytidine deaminase 152
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 152
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family 151
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 150
9-ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities 150
Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1 149
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 148
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors 147
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 147
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 147
Adenosine deaminase: Functional implications and different classes of inhibitors 146
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 146
Biomarkers mapping of neuropathic pain in a nerve chronic constriction injury mice model 146
2-Substituted N-ethylcarboxamidoadenosine derivatives as high affinity agonists at human A(3) adenosine receptors 145
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 144
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. 144
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 144
Adenosine deaminase inhibitors: synthesis and structure-activity relationships of 2-hydroxy-3-nonyl derivatives of azoles 144
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 144
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 143
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 143
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 143
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 142
Chemical and pharmacological profile of selective adenosine receptor agonists 142
Ring opening reactions: synthesis of AICAR analogs as potential antimetabolite agents 140
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 139
Synthesis and receptor affinity of polysubstituted adenosines 139
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 139
Diazepinone nucleosides as inhibitors of cytidine deaminase 138
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 138
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 138
Unexpected synthesis of acyclic adenine nucleosides 137
Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity 137
Synthesis and adenosine deaminase inhibitory activity of 3’-deoxy-1-deazaadenosines 137
Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor 136
Potent and selective ligands for adenosine binding sites 136
Coupling of 2,6-disubstituted purines to ribose-modified sugars 135
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 135
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists 135
Adenosine receptor modeling: what does the A2A crystal structure tell us? 133
Antiviral properties of deazaadenine nucleoside derivatives 132
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 129
Coupling of 2,6-dichloropurine and 2,6-dichlorodeazapurines with ribose and ribose modified sugars 128
Structure-activity relationships of adenosine deaminase inhibitors 128
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 128
2-Alkynyl derivatives of Adenosine-5'-N-ethyluronamide (NECA): selective A2 adenosine receptor agonists with potent inhibitory activity on Platelet aggregation 127
Synthesis and adenosine receptor affinity and potency of 8-alkynyl derivatives of adenosine 126
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 125
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 125
N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A1 adenosine receptor 125
Evidence for the functional expression and pharmacological characterization of adenine receptors in native cells and tissues 124
Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists 124
Modulation of apoptosis in human lymphocytes by adenosine analogues 122
New substituted 9-alkylpurines as adenosine receptor ligands 122
CX3CL1-induced modulation at CA1 synapses reveals multiple mechanisms of EPSC modulation involving adenosine receptor subtypes. 120
Effects of 5 '-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors 119
Characterization of potent ligands at human recombinant adenosine receptors 118
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 118
Well water in central Italy: Analysis of herbicide residues as potential pollutants of untreated crops 117
Synthesis of 1,7-dideazapurine ribonucleosides and deoxyribonucleosides 116
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 113
Adenosine receptor agonists: synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA 113
2- And 8- alkynyladenosines: conformational studies and docking to human adenosine A(3) receptor can explain their different biological behavior 112
Antiviral activity of purine nucleoside analogs against bovine herpesvirus (BHV-1) and maedi visna virus (MVV) 112
P2 receptor antagonists prevent synaptic failure and extracellular signal-regulated kinase ½ activation induced by oxygen and glucose deprivation in rat CA1 hippocampus in vitro 112
Totale 15.808
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.071
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.973 595 224 501 993 291 414 361 457 323 312 179 323
2020/20214.181 166 325 237 316 266 463 731 113 364 210 602 388
2021/20222.229 234 534 55 91 122 119 102 167 170 235 157 243
2022/20232.525 256 144 76 420 277 361 11 154 461 134 165 66
2023/20241.883 265 100 110 76 87 173 87 104 222 62 49 548
2024/2025207 207 0 0 0 0 0 0 0 0 0 0 0
Totale 22.282